The indirect costs of human papillomavirus-related cancer in Central and Eastern Europe: years of life lost and productivity costs

• Published in: Journal of medical economics Vol. 27; no. sup2; p. 1
• Main Authors: Sabale, Ugne, Karamousouli, Eugenia, Popovic, Lazar, Krasznai, Zoárd Tibor, Harrop, Daniel, Meiwald, Anne, Hughes, Robert, Weston, Georgie, Bencina, Goran
• Format: Journal Article
• Language: English
• Published: England 19-04-2024
• Subjects: Adult; Aged; Cost of Illness; Efficiency; Europe - epidemiology; Europe, Eastern - epidemiology; Female; Human Papillomavirus Viruses; Humans; Life Expectancy; Male; Middle Aged; Models, Econometric; Neoplasms - economics; Neoplasms - mortality; Papillomavirus Infections - complications; Papillomavirus Infections - economics; Europe, Eastern; Europe; indirect costs; I18; vaccines; human papillomavirus; I1; I; I10; Cancer; health economics
• ISSN: 1941-837X
• DOI: 10.1080/13696998.2024.2341572

Human papilloma virus (HPV) is a common cause of several types of cancer, including head and neck (oral cavity, pharynx, oropharynx, hypopharynx, nasopharynx, and larynx), cervical, vulval, vaginal, anal, and penile cancers. As HPV vaccines are available, there is potential to prevent HPV-related disease burden and related costs.
A model was developed for nine Central Eastern European (CEE) countries (Bulgaria, Croatia, Czechia, Hungary, Poland, Romania, Serbia, Slovakia, Slovenia). This model considered cancer patients who died from 11 HPV-related cancers (oropharynx, oral cavity, nasopharynx, hypopharynx, pharynx, anal, larynx, vulval, vaginal, cervical, and penile) in 2019. Due to data limitations, Bulgaria only included four cancer types. The model estimated the number of HPV-related deaths and years of life lost (YLL) based on published HPV-attributable fractions. YLL was adjusted with labor force participation, retirement age and then multiplied by mean annual earnings, discounted at a 3% annual rate to calculate the present value of future lost productivity (PVFLP).
In 2019, there were 6,832 deaths attributable to HPV cancers resulting in 107,846 YLL in the nine CEE countries. PVFLP related to HPV cancers was estimated to be €46 M in Romania, €37 M in Poland, €19 M in Hungary, €15 M in Czechia, €12 M in Croatia, €10 M in Serbia, €9 M in Slovakia, €7 M in Bulgaria and €4 M in Slovenia.
There is a high disease burden of HPV-related cancer-related deaths in the CEE region, with a large economic impact to society due to substantial productivity losses. It is critical to implement and reinforce public health measures with the aim to reduce the incidence of HPV-related diseases, and the subsequent premature cancer deaths. Improving HPV screening and increasing vaccination programs, in both male and female populations, could help reduce this burden.